Busulfan, melphalan, and bortezomib compared to melphalan as a high dose regimen for autologous hematopoietic stem cell transplantation in multiple myeloma: long term follow up of a novel high dose regimen

References

• Attal M, Lauwers-Cances V, Hulin C, et al. Lenalidomide, bortezomib,  dexamethasone with transplantation for myeloma. NEJM. 2017;376(14):1311–1320.
   PubMed Web of Science ®Google Scholar
• Costa LJ, Brill IK, Omel J, et al. Recent trends in multiple myeloma incidence and survival by age, race, and ethnicity in the United States. Bld Adv. 2017;1(4):282–287.
   PubMed Web of Science ®Google Scholar
• Hagen P, Stiff P. The role of salvage second autologous hematopoietic cell transplantation in relapsed multiple myeloma. Biol Blood Marrow Transplant. 2019;25(3):e98–e107.
   PubMedGoogle Scholar
• Gore ME, Viner C, Meldrum M, et al. Intensive treatment of multiple myeloma-and criteria for complete remission. Lancet. 1989;334(8668):879–882.
   Google Scholar
• Bayraktar UD, Bashir Q, Qazilbash M, et al. Fifty years of melphalan use in hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2013;19(3):344–356.
   PubMed Web of Science ®Google Scholar
• Valdez BC, Wang G, Murray D, et al. Mechanistic studies on the synergistic cytotoxicity of the nucleoside analogs gemcitabine and clofarabine in multiple myeloma: relevance of p53 and its clinical implications. Exp Hematol. 2013;41(8):719–730.
   PubMed Web of Science ®Google Scholar
• Lonial S, Kaufman J, Tighiouart M, et al. A phase I/II trial combining high-dose melphalan and autologous transplant with bortezomib for multiple myeloma: a dose- and schedule-finding study. Clin Cancer Res. 2010;16(20):5079–5086.
   PubMed Web of Science ®Google Scholar
• de Lima M, Couriel D, Shahjahan M, et al. IV busulfan (Bu) with fludarabine (Flu) or cyclophosphamide (Cy)—comparing ablative preparative regimens for allogeneic transplantation in AML/MDS. Blood. 2004;104(11):97–97.
   Web of Science ®Google Scholar
• Rodriguez TE, Hari P, Stiff PJ, et al. Busulfan, melphalan, and bortezomib versus high-dose melphalan as a conditioning regimen for autologous hematopoietic stem cell transplantation in multiple myeloma. Biol Blood Marrow Transplant. 2016;22(8):1391–1396.
   PubMed Web of Science ®Google Scholar
• Bashir Q, Thall PF, Milton DR, et al. Conditioning with busulfan plus melphalan versus melphalan alone before autologous haemopoietic cell transplantation for multiple myeloma: an open-label, randomised, phase 3 trial. Lancet Haematol. 2019;6(5):e266–e275.
   PubMed Web of Science ®Google Scholar
• Rajkumar SV, Dimopoulos MA, Palumbo A, et al. International myeloma working group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15(12):e538–e548.
   PubMed Web of Science ®Google Scholar
• Durie BGM, Harousseau J-L, Miguel JS, et al. International uniform response criteria for multiple myeloma. Leukemia. 2006;20(9):1467–1473.
   PubMed Web of Science ®Google Scholar
• Kumar SK, Mikhael JR, Buadi FK, et al. Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines. Mayo Clin Proc. 2009;84(12):1095–1110.
   PubMed Web of Science ®Google Scholar
• Greipp PR, San Miguel J, Durie BGM, et al. International staging system for multiple myeloma. J Clin Oncol. 2005;23(15):3412–3420.
   PubMed Web of Science ®Google Scholar
• Jones RJ, Lee KS, Beschorner WE, et al. Venoocclusive disease of the liver following bone marrow transplantation. Transplantation. 1987;44(6):778–783.
   PubMed Web of Science ®Google Scholar
• Rosinol L, Cibeira MT, Martinez J, et al. Bortezomib, lenalidomide and dexamethasone (VRD-GEM) as induction therapy prior Autologous Stem Cell Transplantation (ASCT) in Multiple Myeloma (MM): results of a prospective phase III pethema/GEM trial. Blood. 2008;112 (11):654–654.
   Web of Science ®Google Scholar
• Park S, Kim K, Kim SJ, et al. A phase I/II, open-label, prospective, multicenter study to evaluate theefficacy and safety of lower doses of bortezomib plus busulfan and melphalan as a conditioning regimen in patients with multiplemyeloma undergoing autologous peripheral blood stem celltransplantation: the KMM103 study. Biol Blood Marrow Transplant. 2019;25(7):1312–1319.
   PubMed Web of Science ®Google Scholar
• Jung S-H, Lee J-J, Kim JS, et al. Phase 2 study of an intravenous busulfan and melphalan conditioning regimen for autologous stem cell transplantation in patients with multiple myeloma (KMM150). Biol Blood Marrow Transplant. 2018;24(5):923–929.
   PubMed Web of Science ®Google Scholar
• Lahuerta JJ, Mateos MV, Martínez-López J, et al. Busulfan 12 mg/kg plus melphalan 140 mg/m2 versus melphalan 200 mg/m2 as conditioning regimens for autologous transplantation in newly diagnosed multiple myeloma patients included in the PETHEMA/GEM2000 study. Haematologica. 2010;95(11):1913–1920.
   PubMed Web of Science ®Google Scholar
• Corre J, Cleynen A, Robiou Du Pont S, et al. Multiple myeloma clonal evolution in homogeneously treated patients. Leukemia. 2018;32(12):2636–2647.
   PubMed Web of Science ®Google Scholar
• McCarthy PL, Holstein SA, Petrucci MT, et al. Lenalidomide maintenance after autologous stem-cell transplantation in newly diagnosed multiple myeloma: a meta-analysis. J Clin Oncol. 2017;35(29):3279–3290.
   PubMed Web of Science ®Google Scholar
• Gomez-Arteaga A, Mark TM, Guarneri D, et al. High-dose bendamustine and melphalan conditioning for autologous stem cell transplantation for patients with multiple myeloma. BMT. 2019;54(12):2027–2038.
   Google Scholar
• Shah G, Lin A, Schofield R, et al. Feasibility, tolerability, and patient-reported outcomes with pharmacokinetic (PK)-directed dosing of Evomela® (propylene glycol free melphalan) for multiple myeloma and AL amyloidosis patients undergoing Autologous Hematopoietic Stem Cell Transplant (AHCT). Blood. 2017;130:2023.
   Web of Science ®Google Scholar
• Dhakal B, D'Souza A, Lakshman A, et al. Pharmacokinetics of high-dose propylene glycol-free melphalan in multiple myeloma patients undergoing autologous hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2018;24(8):1610–1614.
   PubMed Web of Science ®Google Scholar
• Ma MH, Yang HH, Parker K, et al. The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents. Clin Cancer Res. 2003;9(3):1136–1144.
   PubMed Web of Science ®Google Scholar
• Blanes M, Lorenzo JI, Ribas P, et al. Intravenous busulfan plus melphalan versus melphalan alone as conditioning regimen for patients with multiple myeloma. Ann Hematol. 2019;98(8):2013–2015.
   PubMed Web of Science ®Google Scholar
• Byun JM, Lee J, Shin S-J, et al. Busulfan plus melphalan versus high-dose melphalan as conditioning regimens in autologous stem cell transplantation for newly diagnosed multiple myeloma. Blood Res. 2018;53(2):105–109.
   PubMed Web of Science ®Google Scholar
• Barta S, Jain R, Mazumder A, et al. Pharmacokinetics-directed Intravenous busulfan combined with high-dose melphalan and bortezomib as a conditioning regimen for patients with multiple myeloma. Clin Lymphoma Myeloma Leuk. 2017;17(10):650–657.
   PubMed Web of Science ®Google Scholar